What is new
Taiwan FDA's September 21 overseas-alert notice urges consumers not to buy the named cream from overseas, online or other sellers. It relays Singapore's earlier action, not a newly announced Taiwanese laboratory finding.
Singapore's action was batch-specific
HSA recalled two Venus Beauty Pte. Ltd. batches on August 26, publishing the notice August 28: 2E122I.2E117I and 2E191G.2E193G. Retail and wholesale suppliers were told to stop supply and return stock.
HSA reported minute amounts of Sudan IV in those samples. It did not detect the dye in samples from APR SG or Rirora International, permitted unaffected batches to resume sale, and required accredited-laboratory testing of every batch those three companies intended to supply locally.
Advice without a blanket risk claim
In its August 28 advice, HSA said serious harm from previous use was unlikely, but consumers should stop using affected products and ask the seller about refund concerns. It reported no local adverse-event reports at that time; that is not a current worldwide safety count.
Grade A applies to the documented official actions, not skincare efficacy. These are regulator notices, not sponsored product studies. Sources checked September 22, 2026; the Taiwan notice is summarized from Traditional Chinese.
Open the source file
These links support the claims above. Source dates, disclosures and limits are documented in the article and source list.
- Taiwan FDA — overseas cosmetic alert (Traditional Chinese) (opens in a new tab)September 21, 2026
- Singapore HSA — Medicube batch recall (opens in a new tab)Notice: August 28; recall: August 26, 2026
- Singapore HSA — testing results and consumer advice (opens in a new tab)August 28, 2026